Institut Rosell Extends European ReachInstitut Rosell Extends European Reach
December 17, 2007
MONTREALInstitut Rosell-Lallemand announced dietary supplements featuring its probiotic, Lactobacillus plantarum 299v, which has been studied for the treatment of irritable bowel syndrome (IBS), were launched in the Czech Republic and in Greece. In addition, the companys French distributor, Merck Medication Familiale, extended its Lp299v offerings, adding a capsule form to its existing sachet format. In the Czech market, Institut Rosell signed an exclusive distribution agreement with Rougier s.r.o., making the Lp299v capsules available through pharmacies and health care retailers. In Greece, the product is marketed in a sachet form by Smart Intermed.
We are very pleased with these two new partnerships for Lp299v in Europe, said Valérie Delahaye-Sarraute, global business director of Institut Rosell-Lallemand (www.Lallemand.com). Our collaboration with Rougier is the product of a solid, long-term relationship that has already seen the company successfully launch our primary probiotic offerings in the Czech Republic. Lp299v is our first product to penetrate the Greek market, and we are confident in the ability of our new partner, Smart Intermed, to develop awareness of the health benefits of Zenbis among Greek health care professionals.
You May Also Like
The ashwagandha root production process: Where tradition meets science – article part threeSep 21, 2023
Former FDA employees weigh in on gov’t shutdownSep 27, 2023
HerbalGram celebrates 40 years of bringing ancient herbal traditions back to life in AmericaSep 27, 2023
New science advances probiotics, milk fats and herbsSep 27, 2023